Significant pain decrease in children with non-systemic Juvenile Idiopathic Arthritis treated to target: results over 24 months of follow up

Table 2 Effect of baseline characteristics on pain over time

	Univariate Analysis			Mulitvariate Analysis
	β	p-value	95% CI	β	p-value	95% CI
VAS Pain (0-100mm)	0.59	< 0.001	0.41; 0.77	0.46	< 0.001	0.25; 0.66
VAS Physician (PGA) (0-100mm)	0.10	0.502	-0.19; 0.40	-0.31	0.013	-0.56; -0.07
VAS patient/parent general wellbeing (0-100mm)	0.36	< 0.001	0.16; 0.57	-0.02	0.831	-0.22; 0.18
Diagnosis
Poly	2.44	0.744	-12.19; 17.07	-3.84	0.520	-15.51; 7.84
Psoriatic	9.50	0.297	-8.37; 27.38	-2.42	0.750	-17.34; 12.49
No. of active joints	1.20	< 0.001	0.59; 1.81	0.81	0.008	0.21; 1.41
PhS (0–100)	-.0.70	< 0.001	-1.01; -0.38	-0.41	0.011	-0.72; -0.10
PsS (0–100)	-.0.51	0.014	-0.91; -0.10	-0.40	0.036	-0.77; -0.03
Symptom duration (mo.)	8.41	0.147	-3.00; 19.82	8.30	0.117	-2.12; 18.72
NSAID use (yes)	-7.61	0.252	-20.64; 5.41	-0.93	0.858	-11.12; 9.26

Effect of baseline characteristics on pain over time. Included baseline variables in univariate and multivariate analysis; VAS pain, VAS physician, VAS patient/parent general wellbeing, diagnosis, number of active joints, PhS, PsS, symptom duration and NSAID use. VAS Visual Analogue Score, No. number, PhS Physical Summary Score, PsS Psychosocial Summary Score, Mo. months

ISSN: 1546-0096